Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome.

Leukemia research - 1 Aug 2009

Butterfield Joseph H

Abstract excerpt

Presence of the oncogenic mutation FIP1L1-PDGFRalpha in hypereosinophilic patients is predictive of hematologic response to imatinib mesylate. However, most patients with hypereosinophilic syndrome (HES) do not have this mutation and have not responded to imatinib doses traditionally successful in patients who test positive for FIP1L1-PDGFRalpha. A patient with FIP1L1-PDGFRalpha-negative HES who had intolerance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Inflammatory Agents
Share to Hydroxyurea
Share to Hypereosinophilic Syndrome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Interferon alpha-2

Share to mRNA Cleavage and Polyadenylation Factors

Share to Prednisolone

Share to Receptor, Platelet-Derived Growth Factor alpha

Source

Identifiers

PMID: 19144405
DOI: 10.1016/j.leukres.2008.12.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome.PMID 19144405Read ↗

Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.Semantic proximity Read ↗

Imatinib for the treatment of hypereosinophilic syndromes.Semantic proximity Read ↗

Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.Semantic proximity Read ↗

Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.Semantic proximity Read ↗

Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder.Semantic proximity Read ↗

Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.Semantic proximity Read ↗

Exquisite response to imatinib mesylate in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome: a 12-year experience of the Polish Hypereosinophilic Syndrome Study Group.Semantic proximity Read ↗

The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and managementSemantic proximity Read ↗

FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.Semantic proximity Read ↗

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.Semantic proximity Read ↗

A Tyrosine Kinase Created by Fusion of the <i>PDGFRA</i> and <i>FIP1L1</i> Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic SyndromeSemantic proximity Read ↗

FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.